Precision Business Insights has published a report on the global biologics contract manufacturing market, estimating its value at USD 21,060 Million in 2024 and is expected to expand at a compound annual growth rate (CAGR) of 9.4% over the forecast period 2025-2031. The report explores the market growth and potential opportunities in the market industry. Additionally, it offers a detailed...

The Fill Finish Manufacturing Market was valued at USD 16.73 billion in 2024 and is expected to grow at a CAGR of 8.7%, reaching USD 38.53 billion by 2034. Rising demand for injectable biologics, vaccines, and sterile drugs, coupled with technological advancements in automated filling and packaging solutions, is propelling the market forward. Fill finish...

Biologics — including monoclonal antibodies, gene therapies, and vaccines — are exerting a transformative influence on the Pharmaceutical Glass Packaging Market. These large-molecule drugs are highly sensitive to environmental conditions, requiring packaging with exceptional chemical inertness, thermal stability, and sterility. As a result, demand for Type I borosilicate glass vials...

Retinal Biologics Market Overview The global retinal biologics market size was valued at USD 24.43 billion in 2024 and is projected to grow from USD 26.08 billion in 2025 to USD 43.98 billion by 2033, growing at a CAGR of 6.75% during the forecast period (2025-2033). Download Exclusive Research Report PDF Sample: (Including...

(IMR) today released a comprehensive analysis of the Global Allergic Conjunctivitis Market , forecasting growth from USD 4.3 billion in 2023 to USD 6.39 billion by 2032 , at a compound annual growth rate (CAGR) of 4.5% over the 2024–2032 period. This growth is being fueled by increasing global incidence of allergic eye disorders, rising environmental allergen exposure, and growing...

Introspective Market Research (IMR) has unveiled its latest strategic analysis on the Global Osteogenesis Imperfecta (OI) Treatment Market . The report highlights the critical role of specialized pharmaceuticals and emerging gene therapies in managing this rare, inherited connective tissue disorder, often referred to as "brittle bone disease." The market, which was valued at USD 722.9 Million...